Topikal D Vitamini Tedavisi, Tedavi Yönetimi ve Kullanıldığı Hastalıklar
Özet
Deride D vitamini analogları, keratinositler ve bağışıklık hücreleri üzerindeki D vitamini reseptörleri (VDR) ile etkileşime girerek proliferasyonu inhibe eder, farklılaşmayı uyarır ve antienflamatuvar etkiler gösterir. Plak tipi psöriyazis ve çeşitli dermatolojik hastalıkların tedavisinde kullanılan kalsitriol, kalsipotriol, maksakalsitol ve takalsitol gibi topikal ajanlar mevcuttur. Kalsitriol, kalsiyum homeostazı için gerekli aktif form olup kalsipotriole göre daha iyi bir güvenlik ve lokal tolerans profiline sahiptir. Sentetik bir türev olan kalsipotriol, psöriyaziste çok güvenli ve etkilidir; yüz ve hassas bölgeler için merhem formuna kıyasla daha az iritan olan ve kozmetik olarak tercih edilen krem formu çocuklarda ve kadınlarda öne çıkar. Maksakalsitol, keratinosit proliferasyonunu güçlü şekilde baskılarken kalsipotriole göre eritem ve skuamı azaltmada daha etkilidir. Takalsitol ise günlük tek doz rejimiyle hasta uyumu sağlar ve diğer analoglara kıyasla daha az deri iritasyonuna neden olur. Bu topikal vitamin D analogları, psöriyazis dışında liken planus, vitiligo, iktiyozlar, siğiller ve morfea gibi çok geniş bir dermatolojik hastalık grubunun tedavisinde de başarıyla uygulanmaktadır.
Vitamin D analogs in the skin exhibit anti-inflammatory effects, inhibit proliferation, and stimulate differentiation by interacting with vitamin D receptors (VDR) on keratinocytes and immune cells. Topical agents such as calcitriol, calcipotriol, maxacalcitol, and tacalcitol are utilized in the treatment of plaque psoriasis and various dermatological disorders. Calcitriol, the active form required for calcium homeostasis, offers similar efficacy but a significantly better safety and local tolerance profile compared to calcipotriol. Calcipotriol, a synthetic derivative, is highly effective in psoriasis; its cream formulation is less irritating than the ointment, preferred cosmetically, and suitable for sensitive areas, facial use, children, and female patients. Maxacalcitol strongly suppresses keratinocyte proliferation and demonstrates superior efficacy in reducing erythema and scaling compared to calcipotriol. Tacalcitol provides a compliance advantage with its once-daily regimen and causes less skin irritation than other analogs. Beyond psoriasis, these topical vitamin D analogs are successfully applied across a wide spectrum of dermatological conditions, including lichen planus, vitiligo, ichthyoses, warts, and morphea.
Referanslar
Van de Kerkhof PCM. Psoriasis. In: Bolognia J, Jorizzo J, Rapini R, editors. Dermatology. London, New York: Mosby; 2003: 127–38.
Milde P, Hauser U, Simon T, et al. Expression of 1,25-dihydroxyvitamin D3 receptors in normal and psoriatic skin. J. Invest. Dermatol. 1991;97:230–9.
Kang S, Yi S, Griffiths CE, et al. Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions. Br J Dermatol. 1998 Jan;138(1):77-83. doi: 10.1046/j.1365-2133.1998.02029.x.
Ashcroft DM, Po AL, Williams HC, Griffiths CE. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ 2000;320:963–7.
Takahashi H, Ibe M, Kinouchi M, et al. Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation. J Dermatol Sci 2003;31:21–8.
Berth-Jones J, Hutchinson PE. Vitamin D analogues and psoriasis. Br J Dermatol 1992;127:71–8.
Bleiker TO, Bourke JF, Mumford R, Hutchinson PE. Long-term outcome of severe chronic plaque psoriasis following treatment with high-dose topical calcipotriol. Br J Dermatol 1998;139:285–6.
Wat H, Dytoc M. Off-label uses of topical vitamin D in dermatology: a systematic review. J Cutan Med Surg. 2014 Mar-Apr;18(2):91-108.
Uliasz A, Lebwohl M. Erdem T. Diğer Topikal Tedaviler. In: Bolognia JL, Jorizzo JL, Rapini RP (eds), Sarıcaoğlu H, Başkan EB (çeviri editörleri). Dermatoloji. Türkçe 1. Baskı.(cilt 1) İstanbul, Nobel Tıp Kitabevleri, 2012;1991-2003.
Rizova E, Corroller M. Topical calcitriol--studies on local tolerance and systemic safety. Br J Dermatol. 2001 Apr;144 Suppl 58:3-10. doi: 10.1046/j.1365-2133.2001.144s58003.x.
Müller K, Diamant M, Bendtzen K. Inhibition of production and function of interleukin-6 by 1,25-dihydroxyvitamin D3. Immunol Lett. 1991 May;28(2):115-20. doi: 10.1016/0165-2478(91)90108-m.
Larsen CG, Kristensen M, Paludan K, et al. 1,25(OH)2-D3 is a potent regulator of interleukin-1 induced interleukin-8 expression and production. Biochem Biophys Res Commun. 1991 May 15;176(3):1020-6. doi: 10.1016/0006-291x(91)90384-j.
Trémezaygues L, Reichrath J. Vitamin D analogs in the treatment of psoriasis: Where are we standing and where will we be going? Dermatoendocrinol. 2011;3(3):180-6. doi: 10.4161/derm.3.3.17534.
Queille-roussel C, Duteil L, Parneix-spake A, et al. The safety of calcitriol 3 microg/g ointment. Evaluation of cutaneous contact sensitization, cumulative irritancy, photoallergic contact sensitization and phototoxicity. Eur J Dermatol. 2001;11:219–24.
Kragballe K, Wildfang IL. Calcipotriol (MC 903), a novel vitamin D3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. Arch Dermatol Res. 1990;282(3):164-7.
Cather J, Menter A. Novel therapies for psoriasis. Am J Clin Dermatol 2002; 3: 159–73.
Binderup L, Bramm E. Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol. 1988;37(5):889-95.
Ramsay CA, Berth-Jones J, Brundin G, et al. Long-term use of topical calcipotriol in chronic plaque psoriasis. Dermatology. 1994;189(3):260-4.
Mortensen L, Kragballe K, Wegmann E, et al. Treatment of psoriasis vulgaris with topical calcipotriol has no short-term effect on calcium or bone metabolism. A randomized, double-blind, placebo-controlled study. Acta Derm Venereol. 1993 Aug;73(4):300-4.
Kragballe K, Gjertsen BT, De Hoop D, et al. Doubleblind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991; 337: 193–6.
Pariser DM, Pariser RJ, Breneman D, et al. Calcipotriene ointment applied once a day for psoriasis: a double-blind, multicenter, placebo-controlled study. Arch Dermatol. 1996;132(12):1527.
Stadler R, Bohmeyer J. [Regarding the effectiveness and tolerability of a cream containing calcipotriol (PsorcutanH) in the treatment of psoriasis vulgaris.] Z Hautkr. 1998;73:593–6.
Schlehaider UK, Kowalzick L. Cream based calcipotriol for the treatment of ‘inverse’ psoriasis and seborrheic dermatitis. Aktuelle Derm. 1996;22:345–8.
Segaert S, Duvold LB. Calcipotriol cream: a review of its use in the management of psoriasis. J Dermatolog Treat. 2006;17(6):327-37. doi: 10.1080/09546630600999219.
Pauluzzi P, Doria A, Nobile C, Trevisan G. Calcipotriol cream in childhood psoriasis. Acta Dermatovenerol Alp Panonica Adriat. 1999;8:119–21.
Ortonne JP, Humbert P, Nicolas JF, et al. Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg/g ointment and calcipotriol 50 microg/g ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas. Br J Dermatol 2003; 148:326-33.
Komine M, Watabe Y, Shimaoka S, et al. The action of a novel vitamin D3 analogue, OCT, on immunomodulatory function of keratinocytes and lymphocytes. Arch Dermatol Res. 1999;291(9):500-6. doi: 10.1007/s004030050444.
Barker JN, Ashton RE, Marks R, et al. Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator. Br J Dermatol 1999; 141: 274–278.
Camarasa JM, Ortonne JP, Dubertret L. Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy. J Dermatolog Treat. 2003 Jan;14(1):8-13. doi: 10.1080/09546630305545.
Hau CS, Shimizu T, Tada Y, et al. The vitamin D3 analog, maxacalcitol, reduces psoriasiform skin inflammation by inducing regulatory T cells and downregulating IL-23 and IL-17 production. J Dermatol Sci. 2018 Nov;92(2):117-126. doi: 10.1016/j.jdermsci.2018.08.007.
Kim WJ, Song M, Ko HC, et al. Topical tacalcitol ointment can be a good therapeutic choice in erythromelanosis follicularis faciei et colli. J Am Acad Dermatol. 2012 Aug;67(2):320-1.
Bikle DD. Vitamin D metabolism and function in the skin. Mol Cell Endocrinol. 2011;347(1-2):80-9.
Dua I, Aggarwal K, Jain VK. Comparative evaluation of efficacy and safety of calcipotriol versus tacalcitol ointment, both in combination with NBUVB phototherapy in the treatment of stable plaque psoriasis. Photodermatol Photoimmunol Photomed. 2017 Sep;33(5):275-81.
Soleymani T, Hung T, Soung J. The role of vitamin D in psoriasis: a review. Int J Dermatol. 2015 Apr;54(4):383-92.
Van de Kerkhof PC, Berth-Jones J, Griffiths CE, et al. Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis. Br J Dermatol 2002; 146: 414–22.
